The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IPIG 2025 | Trials of interest in PNH: investigating zaltenibart and KP104
In this video, Jens Panse, MD, Aachen University Hospital, Aachen, Germany, briefly comments on upcoming trials and treatment approaches in development for paroxysmal nocturnal hemoglobinuria (PNH). Dr Panse highlights the trial investigating zaltenibart in suboptimal responders (NCT05972967), and mentions KP104, an agent that combines proximal and terminal complement inhibition. This interview took place at the 2nd International PNH Interest Group (IPIG) Conference in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, I’d say the zaltenibart trial, which is one that will come out in suboptimal responders and despite the fact that we have proximals now, I think this every eight week treatment is a very attractive one. And then there’s another compound that’s called KP104, that’s basically a combination of a C5 inhibitor and factor H. So you have proximal and terminal inhibition at the same time...
Yeah, I’d say the zaltenibart trial, which is one that will come out in suboptimal responders and despite the fact that we have proximals now, I think this every eight week treatment is a very attractive one. And then there’s another compound that’s called KP104, that’s basically a combination of a C5 inhibitor and factor H. So you have proximal and terminal inhibition at the same time. It’s a Chinese product that so far only has been shown the proof-of-concept in naive patients but there’s trials going to come out with this product. And I think that’s a very attractive idea because we’re all wondering whether or not proximal or terminal would be the best. In this case you would have both at once and you would have with your factor H that is activated at the level where a complement is activated you would have it specifically working at the site of action and so I think that totally makes sense.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Consulting fees: Alexion, Sobi, Omeros, Sandoz; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Alexion, Amgen, Apellis, AstraZeneca, Blueprint Medicines, BMS, Boehringer Ingelheim, Gilead, MSD, Novartis, Pfizer, Roche, Sanofi, Sobi; Support for attending meetings and/or travel: Alexion, Blueprint Medicines, Boehringer Ingelheim, Novartis, Omeros, Pfizer, Roche, Sobi; Participation on a Data Safety Monitoring Board or Advisory Board: Alexion, Amgen, Apellis, AstraZeneca, Blueprint Medicines, BMS, Boehringer Ingelheim, Gilead, MSD, Novartis, Omeros, Pfizer, Roche, Sanofi, Sobi; Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: www.lichterzellen.de; Receipt of equipment, materials, drugs, medical writing, gifts or other services: Apellis, Blueprint Medicines, Novartis, Roche, Sobi.
